JP2020507625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507625A5 JP2020507625A5 JP2019563697A JP2019563697A JP2020507625A5 JP 2020507625 A5 JP2020507625 A5 JP 2020507625A5 JP 2019563697 A JP2019563697 A JP 2019563697A JP 2019563697 A JP2019563697 A JP 2019563697A JP 2020507625 A5 JP2020507625 A5 JP 2020507625A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- cancer
- substituted
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 47
- 125000005843 halogen group Chemical group 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000001153 fluoro group Chemical group F* 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 11
- 238000006243 chemical reaction Methods 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 239000002904 solvent Substances 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- -1 Ra 1 Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 201000005262 Chondroma Diseases 0.000 claims 3
- 208000005243 Chondrosarcoma Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 3
- 239000003054 catalyst Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 206010024612 Lipoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010046431 Urethral cancer Diseases 0.000 claims 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229910001413 alkali metal ion Inorganic materials 0.000 claims 2
- 150000001345 alkine derivatives Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000013066 combination product Substances 0.000 claims 2
- 229940127555 combination product Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010016629 fibroma Diseases 0.000 claims 2
- 201000011066 hemangioma Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 229910001507 metal halide Inorganic materials 0.000 claims 2
- 150000005309 metal halides Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003444 phase transfer catalyst Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- OCDBSVSDAUHJEL-UHFFFAOYSA-N 2-(3-nitropyridin-2-yl)sulfonylpyrimidine Chemical compound [O-][N+](=O)C1=CC=CN=C1S(=O)(=O)C1=NC=CC=N1 OCDBSVSDAUHJEL-UHFFFAOYSA-N 0.000 claims 1
- QXADFAYSDVLPFZ-UHFFFAOYSA-N 3-nitro-2-(3-nitrothiophen-2-yl)sulfinylpyridine Chemical compound C1=CSC(S(=O)C=2C(=CC=CN=2)[N+]([O-])=O)=C1[N+](=O)[O-] QXADFAYSDVLPFZ-UHFFFAOYSA-N 0.000 claims 1
- YNKBPOMJANIPEO-UHFFFAOYSA-N 3-nitro-2-pyridin-2-ylsulfonylpyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1S(=O)(=O)C1=CC=CC=N1 YNKBPOMJANIPEO-UHFFFAOYSA-N 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 claims 1
- 206010062805 Dysplastic naevus Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010019629 Hepatic adenoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002841 Lewis acid Substances 0.000 claims 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 claims 1
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- ROXDIDAALUSNDU-UHFFFAOYSA-N N-[6-chloro-2-(5-chloro-3-nitropyridin-2-yl)sulfonylpyridin-3-yl]acetamide Chemical compound CC(=O)Nc1ccc(Cl)nc1S(=O)(=O)c1ncc(Cl)cc1[N+]([O-])=O ROXDIDAALUSNDU-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000000035 Osteochondroma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005678 Rhabdomyoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 201000002143 bronchus adenoma Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010255 female reproductive organ cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000006359 hepatoblastoma Diseases 0.000 claims 1
- 201000002735 hepatocellular adenoma Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 150000007517 lewis acids Chemical class 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000022006 malignant tumor of meninges Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000009091 myxoma Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 201000011096 spinal cancer Diseases 0.000 claims 1
- 208000014618 spinal cord cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 C*(C(**)Ic1nc(*)c(C)c(*)c1[N+]([O-])=O)I Chemical compound C*(C(**)Ic1nc(*)c(C)c(*)c1[N+]([O-])=O)I 0.000 description 4
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455639P | 2017-02-07 | 2017-02-07 | |
| US62/455,639 | 2017-02-07 | ||
| US201762594799P | 2017-12-05 | 2017-12-05 | |
| US62/594,799 | 2017-12-05 | ||
| PCT/GB2018/050343 WO2018146469A1 (en) | 2017-02-07 | 2018-02-07 | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507625A JP2020507625A (ja) | 2020-03-12 |
| JP2020507625A5 true JP2020507625A5 (enExample) | 2021-03-11 |
Family
ID=61226606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563697A Pending JP2020507625A (ja) | 2017-02-07 | 2018-02-07 | ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11028067B2 (enExample) |
| EP (1) | EP3580215A1 (enExample) |
| JP (1) | JP2020507625A (enExample) |
| KR (1) | KR20190115013A (enExample) |
| CN (1) | CN110382486A (enExample) |
| AU (1) | AU2018218519B2 (enExample) |
| BR (1) | BR112019016223A2 (enExample) |
| CA (1) | CA3051537A1 (enExample) |
| MA (1) | MA47451A (enExample) |
| MX (1) | MX392000B (enExample) |
| WO (1) | WO2018146469A1 (enExample) |
| ZA (1) | ZA201904967B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| KR20190115012A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 헤테로사이클릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 |
| EP3580203A1 (en) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics AB | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| MX2019009356A (es) | 2017-02-07 | 2019-09-19 | Oblique Therapeutics Ab | Sulfinilpiridinas y su uso en el tratamiento del cancer. |
| CA3091085A1 (en) * | 2018-02-12 | 2019-08-15 | Cinda Pharma Ab | Thioredoxin reductase inhibitors for use in the treatment of cancer |
| WO2020061103A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0031173B1 (en) * | 1979-12-19 | 1983-09-14 | Duphar International Research B.V | New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds |
| AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
| US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
| US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
| DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| US5945425A (en) | 1994-04-29 | 1999-08-31 | G.D. Searle & Co. | Method of using (H+ /K+)ATPase inhibitors as antiviral agents |
| EP0850223A1 (de) | 1995-08-24 | 1998-07-01 | Basf Aktiengesellschaft | N-heterocyclische verbindungen, zwischenprodukte für ihre herstellung, sie enthaltende mittel und ihre verwendung zur bekämpfung von schadpilzen |
| DE19531148A1 (de) | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
| US6191280B1 (en) | 1997-05-30 | 2001-02-20 | Basf Aktiengesellschaft | Method for producing substituted thiopyridines |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| WO1999018096A1 (en) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| ATE236136T1 (de) | 1998-01-16 | 2003-04-15 | Hoffmann La Roche | Benzosulfonderivate |
| ES2254385T3 (es) | 2000-02-29 | 2006-06-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| WO2003068744A1 (en) | 2002-02-18 | 2003-08-21 | Ishihara Sangyo Kaisha, Ltd. | Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same |
| US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| WO2005007621A2 (en) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| HRP20090093T3 (en) | 2004-06-04 | 2009-03-31 | Arena Pharmaceuticals Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006083692A2 (en) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Methods of identifying modulators of bromodomains |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| EP1976495A2 (en) | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| CA2647338A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors-3 |
| EP2061472A4 (en) * | 2006-05-22 | 2010-12-22 | Thioredoxin Systems Ab | BACTERIAL THIOREDOXINE REDUCTASE INHIBITORS AND METHODS OF USING THE SAME |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN101723932B (zh) | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| US9421211B2 (en) * | 2009-05-28 | 2016-08-23 | President And Fellows Of Harvard College | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation |
| NZ598262A (en) | 2009-08-17 | 2014-05-30 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| WO2011099502A1 (ja) | 2010-02-10 | 2011-08-18 | 公立大学法人横浜市立大学 | 神経選択的転写抑制因子NRSFに特異的に結合するmSin3B に結合する化合物の利用 |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| WO2012025638A1 (en) | 2010-08-27 | 2012-03-01 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| AU2013216885B2 (en) | 2012-02-10 | 2017-08-03 | The Board Of Regents Of The University Of Texas System | Modulators of exchange proteins directly activated by cAMP (EPACs) |
| US8946418B1 (en) | 2013-07-10 | 2015-02-03 | Boehringer Ingelheim International Gmbh | Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
| CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
| CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| KR20190115012A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 헤테로사이클릴설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 |
| MX2019009356A (es) | 2017-02-07 | 2019-09-19 | Oblique Therapeutics Ab | Sulfinilpiridinas y su uso en el tratamiento del cancer. |
| EP3580203A1 (en) | 2017-02-07 | 2019-12-18 | Oblique Therapeutics AB | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer |
-
2018
- 2018-02-07 KR KR1020197024694A patent/KR20190115013A/ko not_active Ceased
- 2018-02-07 BR BR112019016223A patent/BR112019016223A2/pt not_active IP Right Cessation
- 2018-02-07 MX MX2019009351A patent/MX392000B/es unknown
- 2018-02-07 MA MA047451A patent/MA47451A/fr unknown
- 2018-02-07 AU AU2018218519A patent/AU2018218519B2/en not_active Ceased
- 2018-02-07 WO PCT/GB2018/050343 patent/WO2018146469A1/en not_active Ceased
- 2018-02-07 CA CA3051537A patent/CA3051537A1/en active Pending
- 2018-02-07 CN CN201880010198.8A patent/CN110382486A/zh active Pending
- 2018-02-07 EP EP18705461.4A patent/EP3580215A1/en not_active Withdrawn
- 2018-02-07 US US16/484,039 patent/US11028067B2/en not_active Expired - Fee Related
- 2018-02-07 JP JP2019563697A patent/JP2020507625A/ja active Pending
-
2019
- 2019-07-29 ZA ZA2019/04967A patent/ZA201904967B/en unknown